Arthritis Consumer Experts and Cassie and Friends Society have launched a canakinumab access campaign.
Juvenile arthritis (JA) affects approximately 24,000 infants to teens in BC and Canada, or 3 in every 1,000, making it one of the most common causes of chronic disability in children. Ten to 20 percent of those children have systemic juvenile idiopathic arthritis (sJIA), a severe and potentially life-threatening form of the disease – and many can’t get the medication they desperately need.
In partnership with Arthritis Consumer Experts, Cassie and Friends Society is leading a call for the BC Government to drastically improve the outlook of children with sJIA by allowing reimbursement coverage for canakinumab for the small number of children who need it.
Why have we launched our canakinumab access campaign?
Canakinumab is publicly funded in other Canadian provinces/territories but not BC, putting British Columbian children living with sJIA and other autoinflammatory diseases at a horrible disadvantage by denying them access to a life-changing therapy.
The next general election in British Columbia is scheduled for May 9, 2017. What change would you want to see?
Arthritis affects 1 in 5 British Columbia residents, so healthcare to treat the more than 100 different types of the disease is extremely important to the more than 600,000 British Columbians living with the disease. Any party that wishes to become government needs to consider these constituents. To help the parties understand this, Arthritis Consumer Experts (ACE) sent a questionnaire to the candidates of the 2017 BC Provincial Election.
The questionnaire asked the following questions: Continue reading
…oppose changes to planned expansion to BC government’s Reference Drug Plan. Better Pharmacare Coalition eager to work with government to get it right for patients
A recent Better Pharmacare Coalition (BPC) poll has found that British Columbians oppose expansion of the Ministry of Health’s Reference Drug Program based on concerns that expansion could compromise patient health.
The BC government has approved amendments to the Drug Price Regulation that will expand the Ministry of Health’s Reference Drug Program (RDP). In anticipation of this expansion, the BPC conducted an online poll, which found a resounding 82% of British Columbians are concerned that administrators of the BC PharmaCare program will be implementing a policy that tells physicians which medications they can prescribe for patients, even if it goes against physicians’ opinions of the best care for their patients. Continue reading